並列タイトル等エンドシアリン/CD248は骨肉腫の浸潤と転移を抑制する潜在的な治療標的となる可能性がある
一般注記type:Thesis
Endosialin/CD248/tumor endothelial marker 1 is classified as a C-type lectin-like transmembrane receptor, found on the plasma membrane of activated mesenchymal cells, which binds to fibronectin. Although endosialin is expressed at high levels in stem-like cells of sarcomas, its role has not been fully uncovered. The present study aimed to determine whether endosialin expression is associated with tumor progression and metastasis, and whether endosialin has the potential to act as a novel therapeutic target in osteosarcoma (OS) using MORAb-004/ontuxizumab, a humanized monoclonal antibody, which targets the type C lectin domain of endosialin. The results demonstrated that endosialin was highly expressed in OSs with metastatic disease. Furthermore, MORAb-004 had no cytostatic effect on OS cells in vitro and did not change the expression of stem cells and differentiation markers; however, it inhibited migration of OS cells. Taken together, these results suggest that endosialin may play a role in migration, and may be involved in the metastatic process of OSs. Furthermore, MORAb-004 reduces the motility of OS cells, and suppresses invasion and the development of metastatic lesions.
博士（医学）・甲第829号・令和4年3月15日
Copyright: © Kondo et al. This is an open access article distributed under the terms of Creative Commons Attribution License(https://creativecommons.org/licenses/by-nc-nd/4.0/).
identifier:Oncology letters Vol.23 No.2 Article No.42 (2022 Feb)
identifier:17921074
identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/4012
identifier:Oncology letters, 23(2): Article No.42
連携機関・データベース国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）
提供元機関・データベース奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU